Sales & Marketing US drug pricing overhaul: The Inflation Reduction Act (IRA) ... The Inflation Reduction Act (IRA), signed into law in August 2022, marked a historic shift in US healthcare policy by granting Medicare the authority to negotiate prices for certain high-co
Market Access Looking to history to prepare for America’s uncertain future In this podcast episode, Jesse Mendelsohn and Nicole Raleigh discuss what the future might hold for pharma under a second Trump Administration
News Revisionist history on healthcare at the VP debate In the VP debate, Tim Walz and JD Vance were forceful, unexpectedly convivial, and fast and loose with the facts, particularly on healthcare.
Market Access Medicare drug pricing negotiations: What comes next? Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the
Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.